|
1）ACCORD study group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59
|
|
|
|
2）Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007; 298: 2634-43
|
|
|
|
|
|
3）Patil HR, Al Badarin FJ, AL Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012; 110: 826-33
|
|
|
|
|
|
4）Monami M, Ahren B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk：a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 15: 112-20
|
|
|
|
|
|
5）Scirica BM, Bhatt DL, Braunwald E, et al. Saxiagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-26
|
|
|
|
|
|
6）White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-35
|
|
|
|
|
|
7）Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 Diabetes. N Engl J Med. 2015; 373: 232-42
|
|
|
|
|
|
8）Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE：a multicenter, randomized, double-blind trial. Lancet. 2015; 385: 2067-76
|
|
|
|
|
|
9）Scirica BM, Braunwald E, Raz I, et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI53 Randomised Trial. Circulation. 2014; 130: 1579-88
|
|
|
|
|